Xeris Pharmaceuticals (NASDAQ:XERS) Rating Reiterated by Royal Bank of Canada

Xeris Pharmaceuticals (NASDAQ:XERS)‘s stock had its “market perform” rating restated by investment analysts at Royal Bank of Canada in a research report issued on Tuesday, AnalystRatings.com reports. They currently have a $15.00 price objective on the stock. Royal Bank of Canada’s price objective indicates a potential upside of 463.91% from the company’s current price.

XERS has been the subject of several other research reports. SVB Leerink restated a “market perform” rating and issued a $10.00 price objective on shares of Xeris Pharmaceuticals in a research report on Tuesday. Mizuho restated a “buy” rating and issued a $14.00 price objective on shares of Xeris Pharmaceuticals in a research report on Tuesday, May 26th. Zacks Investment Research upgraded shares of Xeris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Saturday. Finally, ValuEngine upgraded shares of Xeris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 30th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $11.40.

Shares of XERS traded down $0.02 on Tuesday, hitting $2.66. The company’s stock had a trading volume of 2,301,735 shares, compared to its average volume of 1,503,159. The company has a market capitalization of $94.35 million, a PE ratio of -0.58 and a beta of 2.10. The company has a debt-to-equity ratio of 2.16, a current ratio of 4.82 and a quick ratio of 4.72. Xeris Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $12.94. The company has a 50 day moving average price of $4.60 and a 200 day moving average price of $4.39.

Xeris Pharmaceuticals (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative net margin of 3,100.00% and a negative return on equity of 323.82%. The firm had revenue of $1.68 million during the quarter, compared to analysts’ expectations of $1.82 million. On average, equities analysts forecast that Xeris Pharmaceuticals will post -3.06 EPS for the current year.

In other news, insider Paul R. Edick purchased 33,000 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was bought at an average price of $3.54 per share, with a total value of $116,820.00. Following the acquisition, the insider now directly owns 95,493 shares of the company’s stock, valued at $338,045.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Patrick Shannon, Jr. purchased 22,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $3.55 per share, with a total value of $78,100.00. Following the acquisition, the insider now directly owns 117,493 shares in the company, valued at $417,100.15. The disclosure for this purchase can be found here. Insiders own 5.95% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. State Street Corp grew its holdings in shares of Xeris Pharmaceuticals by 8.3% in the 1st quarter. State Street Corp now owns 542,031 shares of the company’s stock valued at $1,057,000 after buying an additional 41,630 shares during the period. Royal Bank of Canada grew its holdings in shares of Xeris Pharmaceuticals by 225.1% in the 1st quarter. Royal Bank of Canada now owns 142,710 shares of the company’s stock valued at $278,000 after buying an additional 98,807 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Xeris Pharmaceuticals in the 1st quarter valued at $33,000. ArrowMark Colorado Holdings LLC grew its holdings in shares of Xeris Pharmaceuticals by 21.4% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 2,341,902 shares of the company’s stock valued at $4,567,000 after buying an additional 413,594 shares during the period. Finally, Two Sigma Investments LP boosted its stake in Xeris Pharmaceuticals by 610.3% in the 1st quarter. Two Sigma Investments LP now owns 178,650 shares of the company’s stock worth $348,000 after purchasing an additional 153,498 shares during the period. 62.48% of the stock is owned by institutional investors.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Recommended Story: How Does the Quiet Period Work?

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.